Global Complement-targeted Therapeutics Market Size study, By Indication (Paroxysmal Nocturnal Haemoglobinuria, Atypical Haemolytic Uraemic Syndrome (Ahus)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional

Global Complement-targeted Therapeutics Market Size study, By Indication (Paroxysmal Nocturnal Haemoglobinuria, Atypical Haemolytic Uraemic Syndrome (Ahus)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2028Global Complement-targeted Therapeutics Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Complement-targeted Therapeutics can be defined as therapeutics that modulate the complement system. The complement system, also called as complement cascade, is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, and promote inflammation, as well as attack the pathogen's cell membrane. However, Activation of the complement system results in the pathogenesis of some diseases such as cancer, rheumatic diseases, Alzheimer's disease, autoimmune diseases, age-related macular degeneration, and schizophrenia among others. The increasing incidences of chronic diseases and growing number of clinical research in complement-targeted therapeutics as well as recent collaboration activities are factors that are accelerating the global market demand. For instance, according to World Health Organization – as of 2021, globally around 41 million people lost their lives due to Noncommunicable diseases (NCDs). NCDs are accounted for around 71% of all global deaths. IN NCDs Cardiovascular diseases account for largest number of deaths, or 17.9 million deaths, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). Furthermore, in June 2021, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. entered in a five-year research collaboration. Under this collaboration both the companies would utilize Beam’s proprietary base editing technology to discover new treatments for complement-driven diseases. The companies would work together on six research programs focused on C3 and other complement targets in the eye, liver, and brain. Also, growing prevalence of immune system diseases and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, lack of awareness towards complements deficiency and high treatment cost impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Complement-targeted Therapeutics market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to growing number of clinical trials and presence of leading market players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising healthcare infrastructure and increasing incidences of Noncommunicable diseases in the region, would create lucrative growth prospects for the Complement-targeted Therapeutics market across the Asia Pacific region.

Major market players included in this report are:
Creative Biolabs
Complement UK
Novartis Ag
Alexion Pharmaceuticals, Inc.
Merck & Co., Inc.
Pfizer Inc.
Allergan Plc.
Abbvie
Sino Biological Inc.
Cascade Biotechnology Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Indication
Paroxysmal Nocturnal Haemoglobinuria
Atypical Haemolytic Uraemic Syndrome (Ahus)

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Complement-targeted Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Creative Biolabs
Complement UK
Novartis Ag
Alexion Pharmaceuticals, Inc.
Merck & Co., Inc.
Pfizer Inc.
Allergan Plc.
Abbvie
Sino Biological Inc.
Cascade Biotechnology Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.